The FDA asked CEL-SCI Corporation $CVM to put its  Multikine (Leukocyte Interleukin Injection), a Phase 3 clinical trial in advanced primary head and neck cancer,  on clinical hold. The company expects to get a formal letter in the next 30 days and will work diligently to sort out the matter. The specific reasons for the hold have not been provided. The study, at present, has 926 patients enrolled.